Preoperative hematological indexes used to evaluate the prognosis of gastric cancer patients

Abstract

Zhang Baoying, Cui Jing, Jiang Lei, Guan Quanlin. . Preoperative hematological indexes used to evaluate the prognosis of gastric cancer patients[J]. Journal of International Oncology, 2017, 44(3): 228-230.

References

［1］ Wang W, Chen XL, Zhao SY, et al. Prognostic significance of preoperative serum CA125, CA199 and CEA in gastric carcinoma［J］. Oncotarget, 2016, 7(23): 35423-35436. DOI: 10.18632/oncotarget.8770. ［2］张燕华, 李雁, 陈创, 等. 多种肿瘤标志物与胃癌进展及预后的关系［J］. 武汉大学学报: 医学版, 2009, 30(4): 455-458, 462. DOI: 10.14188/j.16718852.2009.04.031. ［3］ Lai IR, Lee WJ, Huang MT, et al. Comparison of serum CA724, CEA, TPA, CA199 and CA125 levels in gastric cancer patients and correlation with recurrence［J］. Hepatogastroenterology, 2002, 49(46): 1157-1160. ［4］ Yamashita H, Katai H. Systemic inflammatory response in gastric cancer［J］. World J Surg, 2010, 34(10): 2399-2400. DOI: 10.1007/s0026801007031. ［5］ Jiang Y, Xu H, Jiang H, et al. Pretreatment neutrophillymphocyte count ratio may associate with gastric cancer presence［J］. Cancer Biomark, 2016, 16(4): 523-528. DOI: 10.3233/CBM160593. ［6］石朋, 赵毅, 邓鑫. 术前中性粒细胞淋巴细胞比率(NLR)预测胃癌预后的临床意义［J］. 现代肿瘤医学, 2012, 20(5): 987-991. DOI: 10.3969/j.issn.16724992.2012.05.37. ［7］ Chen XL, Xue L, Wang W, et al. Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study［J］. Oncotarget, 2015, 6(38): 41370-41382. DOI: 10.18632/oncotarget.5629. ［8］ Xu L, Zhou X, Wang J, et al. The hematologic markers as prognostic factors in patients with resectable gastric cancer［J］. Cancer Biomark, 2016, 17(3): 359-367. DOI: 10.3233/cbm160648. ［9］ Sun X, Liu X, Liu J, et al. Preoperative neutrophiltolymphocyte ratio plus platelettolymphocyte ratio in predicting survival for patients with stage ⅠⅡ gastric cancer［J］. Chin J Cancer, 2016, 35(1): 57. DOI: 10.1186/s40880 01601222. ［10］ Liu X, Sun X, Liu J, et al. Preoperative Creactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer［J］. Transl Oncol, 2015, 8(4): 339-345. DOI: 10.1016/j.tranon.2015.06.006. ［11］ Ishino Y, Saigusa S, Ohi M, et al. Preoperative Creactive protein and operative blood loss predict poor prognosis in patients with gastric cancer after laparoscopyassisted gastrectomy［J］. Asian J Endosc Surg, 2014, 7(4): 287-294. DOI: 10.1111/ases.12126. ［12］ Liu BZ, Tao L, Chen YZ, et al. Preoperative body mass index, blood albumin and triglycerides predict survival for patients with gastric cancer ［J］. PLoS One, 2016, 11(6): e0157401. DOI: 10.1371/journal.pone.0157401. ［13］孙晓春. C反应蛋白与胃癌相关性的meta分析［D］ . 重庆: 重庆医科大学, 2014. ［14］李慕行, 毕新宇, 李智宇, 等. 格拉斯哥评分对肝细胞肝癌患者的预后影响的荟萃分析［J］. 肝癌电子杂志, 2015, 2(3): 31-36. ［15］ Zhang CX, Wang SY, Chen SQ, et al. Association between pretreatment Glasgow prognostic score and gastric cancer survival and clinicopathological features: a metaanalysis［J］. Onco Targets Ther, 2016, 9: 3883-3891. DOI: 10.2147/ ott.s103996. ［16］贺淑霞, 雷晓丽. 血浆纤维蛋白原水平与恶性肿瘤的生长转移关系［J］. 宁夏医学院学报, 2007, 29(5): 508-509. DOI: 10.3969/j.issn.16746309.2007.05.027. ［17］ Yu X, Hu F, Yao Q, et al. Serum fibrinogen levels are positively correlated with advanced tumor stage and poor survival in patients with gastric cancer undergoing gastrectomy: a large cohort retrospective study［ J］. BMC Cancer, 2016, 16(1): 480. DOI: 10.1186/s128850162510z. ［18］ Yamamoto M, Kurokawa Y, Miyazaki Y, et al. Usefulness of preoperative plasma fibrinogen versus other prognostic markers for predicting gastric cancer recurrence［J］. World J Surg, 2016, 40(8): 1904 -1909. DOI: 10.1007/s00268016 34745. ［19］ Tamura T, Inagawa S, Hisakura K, et al. Evaluation of serum highdensity lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients［J］. J Gastroenterol Hepatol, 2012, 27(10): 1635- 1640. DOI: 10.1111/j.1440 1746.2012.07189.x. ［20］李旭哲, 刘斌正, 马雅静, 等. 胃癌患者术前血液中钾、钠、氯、镁、磷的相关性及其对生存预后的影响［J］. 中国现代医学杂志, 2016, 26(11): 34-39. DOI: 10.3969/ j.issn.10058982.2016.11.007.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[6]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197.
[7]	Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209.
[8]	Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222.
[9]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[10]	Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165.
[11]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[12]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[13]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[14]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[15]	Huang Zhen, Chen Yongshun.Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2024, 51(1): 59-64.